118 related articles for article (PubMed ID: 7835805)
1. Genetic, biochemical, and multimodal approaches to screening for ovarian cancer.
Jacobs I
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S22-7. PubMed ID: 7835805
[No Abstract] [Full Text] [Related]
2. Personalizing ovarian cancer screening.
Goozner M
J Natl Cancer Inst; 2010 Aug; 102(15):1112-3. PubMed ID: 20668268
[No Abstract] [Full Text] [Related]
3. Familial ovarian cancer screening.
Stirling D; Porteous ME; Evans DG; Pichert G; Steel M
J Clin Oncol; 2006 Feb; 24(6):e11. PubMed ID: 16484689
[No Abstract] [Full Text] [Related]
4. [Screening for ovarian cancers: critical analysis].
Pennehouat G; Gugliemina JN; Naouri M; Créquat J; Bouret JM; Thébault Y; Madelenat P
Contracept Fertil Sex; 1993 Mar; 21(3):223-30. PubMed ID: 7951617
[TBL] [Abstract][Full Text] [Related]
5. A step forward for two-step screening for ovarian cancer.
Hensley ML
J Clin Oncol; 2010 May; 28(13):2128-30. PubMed ID: 20368556
[No Abstract] [Full Text] [Related]
6. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women.
Skates SJ; Menon U; MacDonald N; Rosenthal AN; Oram DH; Knapp RC; Jacobs IJ
J Clin Oncol; 2003 May; 21(10 Suppl):206s-210s. PubMed ID: 12743136
[TBL] [Abstract][Full Text] [Related]
7. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
8. [Mass-screening for ovarian cancer].
Sato S; Higuchi T; Yokoyama Y; Sakamoto T
Nihon Rinsho; 2004 Oct; 62 Suppl 10():601-4. PubMed ID: 15535316
[No Abstract] [Full Text] [Related]
9. CA-125: a biomarker put to the test.
Schmidt C
J Natl Cancer Inst; 2011 Sep; 103(17):1290-1. PubMed ID: 21852262
[No Abstract] [Full Text] [Related]
10. [Expression of CA-125 in ovarian cancer].
Mircea R; Frîncu DL; Dumitrache F
Rev Med Chir Soc Med Nat Iasi; 2009; 113(4):1191-4. PubMed ID: 20191897
[TBL] [Abstract][Full Text] [Related]
11. How appropriate are the american college of radiology appropriateness criteria for ovarian cancer screening.
Dubinsky TJ
Ultrasound Q; 2010 Dec; 26(4):225-6. PubMed ID: 21084937
[No Abstract] [Full Text] [Related]
12. Circulating tumour markers in ovarian tumours.
von Schlippe M; Rustin GJ
Forum (Genova); 2000; 10(4):383-92. PubMed ID: 11535987
[TBL] [Abstract][Full Text] [Related]
13. The value of cancer antigen 125 (CA 125) during treatment and follow-up of patients with ovarian cancer.
de Bruijn HW; van der Zee AG; Aalders JG
Curr Opin Obstet Gynecol; 1997 Feb; 9(1):8-13. PubMed ID: 9090475
[TBL] [Abstract][Full Text] [Related]
14. Monitoring ovarian cancer: CA125 trial stirs controversy.
Chitale R
J Natl Cancer Inst; 2009 Sep; 101(18):1233-5. PubMed ID: 19738165
[No Abstract] [Full Text] [Related]
15. Screening for ovarian cancer.
Jacobs I; Oram D
Biomed Pharmacother; 1988; 42(9):589-96. PubMed ID: 3071382
[TBL] [Abstract][Full Text] [Related]
16. Ovarian cancer screening. American College of Radiology. ACR Appropriateness Criteria.
Böhm-Vélez M; Mendelson E; Bree R; Finberg H; Fishman EK; Hricak H; Laing F; Sartoris D; Thurmond A; Goldstein S
Radiology; 2000 Jun; 215 Suppl():861-71. PubMed ID: 11037511
[No Abstract] [Full Text] [Related]
17. Screening and detection of ovarian cancer.
Breedlove G; Busenhart C
J Midwifery Womens Health; 2005; 50(1):51-4. PubMed ID: 15637515
[TBL] [Abstract][Full Text] [Related]
18. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
[TBL] [Abstract][Full Text] [Related]
19. [15 years CA-125 antigen: usefulness and limits. Apropos of 3 clinical cases].
Petignat P; Vajda D; Obrist R
Praxis (Bern 1994); 1998 Nov; 87(47):1602-5. PubMed ID: 9865132
[TBL] [Abstract][Full Text] [Related]
20. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.
Hermsen BB; von Mensdorff-Pouilly S; Berkhof J; van Diest PJ; Gille JJ; Menko FH; Blankenstein MA; Kenemans P; Verheijen RH
J Clin Oncol; 2007 Apr; 25(11):1383-9. PubMed ID: 17416858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]